Signos Prescription Process: How the Intake, CGM, and Medication Pathway Works

How the Signos Intake Process Works

Signos routes new members through a four-step digital intake that mirrors the asynchronous telehealth model used by most direct-to-consumer weight management platforms. The entire process is remote. No clinic visit is required.

Step one is an online questionnaire covering medical history, current medications, allergies, weight loss goals, and metabolic conditions such as type 2 diabetes or prediabetes. This form takes roughly 10 to 15 minutes and collects the clinical data a prescribing provider needs to evaluate candidacy. Signos asks about prior use of GLP-1 agonists, bariatric surgery history, and family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, both of which are contraindications for GLP-1 receptor agonists per FDA labeling [1].

Step two is a provider review. A licensed clinician (physician, nurse practitioner, or physician assistant depending on state) evaluates the submitted information. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends that anti-obesity medication decisions account for BMI, comorbidities, prior treatment response, and patient preference [2]. Signos states its providers follow similar criteria, though the depth of that evaluation in an asynchronous model is difficult to verify independently.

Step three: if approved, the member receives a CGM prescription and, when appropriate, a weight loss medication prescription. Step four is shipment. The CGM (typically a Dexcom G7 or Abbott Libre 3) arrives by mail, and the medication ships from a partner pharmacy.

What the Medical Questionnaire Covers

The intake questionnaire is the clinical backbone of the Signos process. It determines both CGM eligibility and medication candidacy in a single pass, which means accuracy matters.

Members report their height, weight, age, biological sex, and relevant diagnoses. The form screens for conditions that affect prescribing: thyroid disease, pancreatitis history, gastroparesis, eating disorders, pregnancy or planned pregnancy, and renal impairment. A 2023 review in Obesity Reviews noted that telehealth weight management programs vary widely in the rigor of their intake screening, with some platforms relying on as few as five clinical questions before prescribing [3]. Signos appears to fall on the more thorough end of this spectrum based on publicly available descriptions of its intake, though the company does not publish its full questionnaire.

Certain responses trigger additional requirements. A history of type 2 diabetes, for instance, may prompt a request for recent HbA1c results. BMI below 27 typically disqualifies a member from GLP-1 prescriptions, consistent with FDA-approved indications for semaglutide 2.4 mg (Wegovy), which requires BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity [1]. Members who do not qualify for medication can still enroll in the CGM-only program.

Provider Review and Prescription Decisions

The provider review is asynchronous in most cases. This is standard practice across telehealth weight loss platforms, but it raises a question that has received increasing scrutiny from medical boards: can a provider adequately assess obesity pharmacotherapy candidacy without a synchronous conversation?

The American Telemedicine Association's practice guidelines state that asynchronous care is appropriate when the clinical scenario is well-defined and risk is manageable [4]. Obesity pharmacotherapy, however, carries meaningful risk. GLP-1 receptor agonists can cause nausea, vomiting, pancreatitis, and gallbladder disease. The STEP 1 trial (N=1,961) reported that 44.2% of participants on semaglutide 2.4 mg experienced gastrointestinal adverse events versus 17.4% on placebo [5]. Tirzepatide in the SURMOUNT-1 trial (N=2,539) showed nausea rates of 24.6% at the 5 mg dose and 33.3% at the 15 mg dose [6].

Signos states that providers may request a video or phone consultation when clinical complexity warrants it. The company also notes that prescriptions include dose titration schedules consistent with FDA labeling. Whether this level of oversight matches what a patient would receive from an in-person obesity medicine specialist is an open question. Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, has stated: "Telehealth can work for obesity treatment, but the initial evaluation needs to be comprehensive enough to catch contraindications that patients themselves may not recognize" [7].

How Signos Uses CGM Data for Weight Loss

The CGM component is what distinguishes Signos from pure telehealth GLP-1 platforms like Calibrate or Found. Signos markets glucose data as a personalization tool: the app tracks postprandial glucose spikes, assigns "food scores" to meals, and recommends exercise timing based on real-time glucose trends.

The clinical premise is reasonable. A 2022 randomized controlled trial published in the Journal of Clinical Endocrinology & Metabolism found that CGM-guided dietary counseling in adults with prediabetes led to a 1.1% greater reduction in HbA1c compared to standard counseling at 12 months (P=0.02) [8]. The study population had prediabetes, though, not simple overweight. For individuals without glucose dysregulation, the marginal benefit of CGM over standard calorie tracking is less clear.

A 2023 systematic review in Diabetes Technology & Therapeutics examined CGM use in non-diabetic populations and concluded that while CGM increased dietary awareness, "evidence for sustained weight loss attributable to CGM feedback alone remains insufficient" [9]. The review identified only four RCTs with non-diabetic participants, and none exceeded 16 weeks. Mean weight loss differences between CGM and control groups ranged from 0.4 to 1.8 kg. These are modest effects.

Signos pairs CGM data with behavioral nudges and, for medicated members, correlates glucose patterns with GLP-1 dose timing. This integrated approach has theoretical appeal, but no published trial has evaluated the Signos platform specifically. The evidence supporting CGM for weight loss in metabolically healthy adults remains preliminary.

What Medications Does Signos Prescribe?

Signos has expanded from a CGM-only platform to one that also prescribes weight loss medications. The specific formulary varies based on member eligibility and state regulations, but publicly available information indicates the following options.

Brand-name GLP-1 receptor agonists include semaglutide (Wegovy) and tirzepatide (Zepbound). These are FDA-approved for chronic weight management in adults with BMI of 30 or higher, or BMI of 27 or higher with a weight-related comorbidity [1][10]. The STEP 1 trial demonstrated 14.9% mean body weight reduction with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo [5]. SURMOUNT-1 showed 20.9% mean weight loss with tirzepatide 15 mg at 72 weeks versus 3.1% with placebo [6].

Signos may also offer compounded semaglutide during periods of brand-name shortage, consistent with FDA enforcement discretion guidance for 503A and 503B compounding pharmacies [11]. The FDA's position on compounded GLP-1s has shifted repeatedly since 2023, and members should verify current availability.

Other medications that telehealth weight loss platforms in this category sometimes prescribe include metformin (off-label for weight loss), naltrexone-bupropion (Contrave), and topiramate-phentermine (Qsymia). Signos does not prominently advertise these alternatives, suggesting its clinical pathway favors GLP-1 agonists as the primary pharmacotherapy.

Is Signos Legit? Evaluating the Evidence and Business Model

"Is Signos legit?" is one of the most common queries associated with the brand. The answer depends on what "legit" means to the person asking.

From a regulatory standpoint, Signos operates as a licensed telehealth platform with prescribing providers credentialed in the states where they practice. CGMs are FDA-cleared medical devices, and the GLP-1 medications prescribed through the platform are FDA-approved drugs. The business model itself is legal and comparable to platforms like Calibrate, Found, and Ro Body.

From a clinical evidence standpoint, the situation is more nuanced. The GLP-1 medications Signos prescribes have strong clinical trial support. That evidence belongs to the drugs, not to Signos as a platform. The CGM-for-weight-loss proposition has weaker independent support. A 2021 study in Nutrients found that CGM use increased participant engagement with dietary modification, but the effect on weight was not statistically significant at 12 weeks (mean difference: 0.8 kg, P=0.14) [12].

Consumer reviews of Signos are mixed. Positive reviews tend to highlight the motivational effect of seeing real-time glucose data. Negative reviews frequently cite subscription cost, difficulty canceling, and limited provider interaction. The Better Business Bureau and Trustpilot listings show a pattern common to subscription-based telehealth: high satisfaction among engaged users, frustration among those expecting more hands-on medical care.

The American Medical Association's 2024 policy statement on direct-to-consumer telehealth for weight management cautioned that "platforms offering anti-obesity medications should ensure adequate clinical oversight, follow-up, and patient education, particularly regarding medication discontinuation and weight regain" [13]. Signos members should evaluate whether the level of provider interaction they receive meets their individual clinical needs.

How Much Does Signos Cost?

Signos pricing operates on a tiered subscription model. The CGM-only plan starts around $199 per month and includes sensor shipments and app access. Plans that include GLP-1 medications can cost $299 to $399 or more per month depending on the drug, dose, and whether brand-name or compounded formulations are used.

These prices are in line with competitor platforms. Calibrate charges roughly $199 per month for its metabolic health program (medication cost separate). Ro Body advertises compounded semaglutide starting at $145 per month. Found's pricing ranges from $99 to $199 monthly. None of these include identical services, making direct comparison imperfect.

Insurance coverage for CGMs used outside of diabetes is generally not available. The Centers for Medicare & Medicaid Services covers CGMs for Medicare beneficiaries with diabetes on insulin therapy, but there is no coverage pathway for CGMs prescribed solely for weight management [14]. Most commercial insurers follow similar policies. GLP-1 medications prescribed through telehealth may be covered if the member's insurance plan includes anti-obesity medication benefits and the prescription meets prior authorization criteria.

Cost-effectiveness data for CGM-based weight loss programs do not exist yet. A 2024 analysis in PharmacoEconomics estimated the cost-effectiveness of semaglutide 2.4 mg for obesity at approximately $160,000 per quality-adjusted life year (QALY) at list price, which exceeds the commonly cited $100,000-per-QALY willingness-to-pay threshold [15]. Adding subscription CGM costs on top of medication costs moves the cost-effectiveness ratio further from favorable territory.

Signos vs. Alternatives: How the Platform Compares

Signos occupies a specific niche: CGM-integrated weight loss with optional GLP-1 prescribing. Alternatives fall into two categories.

Pure telehealth GLP-1 platforms (Ro Body, Found, Henry Meds, Calibrate) prescribe the same medications through similar asynchronous intake models. Their advantage is typically lower cost because they do not bundle CGM hardware. Their disadvantage is the absence of real-time metabolic data, though the clinical value of that data for non-diabetic weight loss remains debated.

CGM-focused competitors (Levels, Nutrisense, Veri) provide glucose monitoring and dietary coaching but historically have not prescribed weight loss medications. Some have begun adding prescribing services. The differentiator between these platforms and Signos is primarily the app experience, coaching quality, and pricing structure rather than clinical outcomes, since none have published comparative trials.

A 2024 cross-sectional survey in Obesity Science & Practice found that 62% of adults using direct-to-consumer weight loss platforms reported satisfaction with their program, but only 29% had maintained contact with their prescribing provider beyond the initial three months [16]. This attrition pattern suggests that the choice of platform may matter less than the member's own engagement with follow-up care.

Limitations of the Signos Approach

Three gaps in the Signos model deserve attention.

First, the asynchronous intake may miss clinical complexity. Patients with eating disorders, polycystic ovary syndrome, Cushing syndrome, or hypothalamic obesity may need specialized evaluation that a questionnaire cannot provide. The Endocrine Society recommends screening for secondary causes of obesity before initiating pharmacotherapy [2].

Second, CGM data interpretation requires context. A postprandial glucose spike of 160 mg/dL after a meal means something different in a person with insulin resistance than in a metabolically healthy individual. The American Diabetes Association defines normal postprandial glucose as below 140 mg/dL at two hours [17], but optimal ranges for weight loss in non-diabetic adults have not been established by any major guideline body. Signos uses proprietary thresholds that are not peer-reviewed.

Third, weight regain after GLP-1 discontinuation is substantial. The STEP 1 extension trial showed that participants regained two-thirds of lost weight within one year of stopping semaglutide [18]. Signos does not prominently address long-term medication planning, discontinuation protocols, or transition to maintenance strategies in its public-facing materials. Members should discuss an exit plan with their provider before starting any GLP-1 agonist.

The average weight regain at 52 weeks post-semaglutide cessation was 11.6 percentage points of the 17.3% lost during the active treatment phase [18].